Form D · Pharmaceuticals
Mineralys Therapeutics, Inc.
Radnor, PA · CIK 0001933414
Offering snapshot reported Jun 13, 2022 · SEC filing
- Reported sold
- $118M Offering amount: $118M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 1, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 13, 2022 | Initial | $117,999,994 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-448950
Source: Form D, filed Jun 13, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Srinivas Akkaraju | Director |
| Alexander Asam | Director |
| Jon Congleton | Director, Executive |
| Derek Di Rocco | Director |
| Adam Levy | Executive |
| Olivier Litzka | Director |
| Takeshi Takahashi | Director |
| Brian Taylor Slingsby | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
150 N. Radnor Chester Road Suite F200
Radnor, PA, 19087
Radnor, PA, 19087